4D Pharma Live Discussion

Live Discuss Polls Ratings
Page

dickie3times 09 Apr 2018

250p by June "Oncology candidate"[link] Microbiome Therapeutics Market: Competitive LandscapeKey players identified in the global microbiome therapeutics market are SERES Therapeutics Inc., Rebiotix Inc., OxThera AB, Immuron Ltd., Microbiome Therapeutics Inc., Ferring B.V., Ritter Pharmaceuticals, LNC Therapeutics, Enterome SA, Synlogic Inc., 4D Pharma Plc. AOBiome LLC, Vedanta Biosciences Inc., ViThera Pharmaceuticals Inc., AvidBiotics, Osel Inc. etc. among others.[link]

wheelofsteel 16 Oct 2017

Medical references to biome Another book reference - Brain Maker - heaps of research into gut/brain connection, research on degenerative and autoimmune diseases - and the intimate relationship between microbes and our health.Again - good for info about the general landscape and the potential impact of biotherapeutics which looks to be huge.

wheelofsteel 11 Sep 2017

Fascinating sector Biopharma, based on the developing science of the Human Biome is an intriguing prospect. A good introduction to the Human Biome is 'Missing Microbes'. Might help potential investors get a handle on the broader context

nk1999 22 Dec 2014

From Citywire "4D PharmaCitywire AA-rated Neil Woodford, widely acknowledged as one of the best UK investor of his generation, has continued to up his stake in biotech startup 4D Pharma (DDDD), one of this year's most successful IPOs.Woodford increased his stake in the business from 5.89 million shares to 6.35 million or 12.19% worth more than £21 million at a share price of 333p, up 85% from the 180p they opened trading at in February.In addition to Woodford, the company is also backed by Lansdowne Partners, the UK's biggest hedge fund.Shares in 4D spiked in September when it announced that it would begin clinical trials of its therapies for irritable bowel syndrome and paediatric Crohn's disease.'In addition to the progress in our research and clinical programmes, we have built a strong group of shareholders who share and believe in our vision for 4D,' said company chair Dave Norwood in June."

Page